BIOMAT Database Logo BIOMAT Database Logo

[Antisecretory effects of quamatel and gastrocepin in duodenal ulcer: comparison with intragastric pH-metry]. 1998

A A Sheptulin, and A V Okhlobystin

Antisecretory effect of intravenous quamatel (Q) and gastrocepin (G) was studied in 59 patients with duodenal ulcer. Mean maximal pH and delta-pH in antral portion of the stomach and its body were similar for Q and G, but pH responded to Q administration faster. The antisecretory effect of Q was more pronounced in males and young patients and was inversely proportional to initial acidity.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007419 Intestinal Secretions Fluids originating from the epithelial lining of the intestines, adjoining exocrine glands and from organs such as the liver, which empty into the cavity of the intestines. Intestinal Secretion,Secretion, Intestinal,Secretions, Intestinal
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010890 Pirenzepine An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients. Gastrotsepin,Gastrozepin,L-S 519,LS-519,Piren-Basan,Pirenzepin,Pirenzepin Von Ct,Pirenzepin-Ratiopharm,Pirenzepine Dihydrochloride,Pyrenzepine,Ulcoprotect,Ulgescum,Dihydrochloride, Pirenzepine,LS 519,LS519,Piren Basan,Pirenzepin Ratiopharm,Von Ct, Pirenzepin
D004381 Duodenal Ulcer A PEPTIC ULCER located in the DUODENUM. Curling's Ulcer,Curling Ulcer,Curlings Ulcer,Duodenal Ulcers,Ulcer, Curling,Ulcer, Duodenal,Ulcers, Duodenal
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D005753 Gastric Mucosa Lining of the STOMACH, consisting of an inner EPITHELIUM, a middle LAMINA PROPRIA, and an outer MUSCULARIS MUCOSAE. The surface cells produce MUCUS that protects the stomach from attack by digestive acid and enzymes. When the epithelium invaginates into the LAMINA PROPRIA at various region of the stomach (CARDIA; GASTRIC FUNDUS; and PYLORUS), different tubular gastric glands are formed. These glands consist of cells that secrete mucus, enzymes, HYDROCHLORIC ACID, or hormones. Cardiac Glands,Gastric Glands,Pyloric Glands,Cardiac Gland,Gastric Gland,Gastric Mucosas,Gland, Cardiac,Gland, Gastric,Gland, Pyloric,Glands, Cardiac,Glands, Gastric,Glands, Pyloric,Mucosa, Gastric,Mucosas, Gastric,Pyloric Gland
D006635 Histamine H2 Antagonists Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. Antihistaminics, H2,H2 Receptor Blockader,Histamine H2 Antagonist,Histamine H2 Blocker,Histamine H2 Receptor Antagonist,Histamine H2 Receptor Antagonists,Histamine H2 Receptor Blockader,Histamine H2 Receptor Blockaders,Antagonists, Histamine H2,Blockaders, Histamine H2 Receptor,H2 Receptor Blockaders,Histamine H2 Blockers,Receptor Antagonists, Histamine H2,Receptor Blockaders, H2,Antagonist, Histamine H2,Blockader, H2 Receptor,Blockaders, H2 Receptor,Blocker, Histamine H2,Blockers, Histamine H2,H2 Antagonist, Histamine,H2 Antagonists, Histamine,H2 Antihistaminics,H2 Blocker, Histamine,H2 Blockers, Histamine,Receptor Blockader, H2

Related Publications

A A Sheptulin, and A V Okhlobystin
[Use of intragastric pH-metry in peptic ulcer].
April 1981, Vrachebnoe delo,
A A Sheptulin, and A V Okhlobystin
[Intragastric pH-metry in surgery of gastro-duodenal ulcers].
January 1972, Khirurgiia,
A A Sheptulin, and A V Okhlobystin
Intragastric pH and duodenal ulcer.
March 1989, The British journal of surgery,
A A Sheptulin, and A V Okhlobystin
[Indicators od intragastric pH-metry in complicated ulcer disease].
December 1975, Vrachebnoe delo,
A A Sheptulin, and A V Okhlobystin
[Circadian monitoring of intragastric pH in evaluation of efficiency of antisecretory therapy of duodenal ulcer].
January 2002, Klinicheskaia meditsina,
A A Sheptulin, and A V Okhlobystin
Statistical interpretation of the antisecretory effect of famotidine measured by intragastric pH-metry.
January 1996, European journal of clinical pharmacology,
A A Sheptulin, and A V Okhlobystin
[Continuous intragastric pH-metry].
November 1985, Schweizerische medizinische Wochenschrift,
A A Sheptulin, and A V Okhlobystin
Twenty-four-hour intragastric pH-metry: evidence of nightly gastric alkalinization in subjects with and without active duodenal ulcer.
January 1992, Rivista europea per le scienze mediche e farmacologiche = European review for medical and pharmacological sciences = Revue europeenne pour les sciences medicales et pharmacologiques,
A A Sheptulin, and A V Okhlobystin
Evaluation of antisecretory activity of misoprostol in duodenal ulcer patients using long-term intragastric pH monitoring.
March 1988, Digestive diseases and sciences,
A A Sheptulin, and A V Okhlobystin
24-hour study of intragastric acidity in duodenal ulcer patients and normal subjects using continuous intraluminal pH-metry.
September 1988, Digestive diseases and sciences,
Copied contents to your clipboard!